HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area purity target with related-substance reporting on request.
GLP-1 family · research-use
Tirzepatide OEM supply.
Research use, worldwide.
Lyophilized tirzepatide for research labs and private-label brand evaluation worldwide. ≥99% HPLC purity target, batch-linked COA, HPLC chromatogram and MS identity record.
!
Research use — supplied as research peptides; buyers confirm local compliance
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework. Pending finalization, tirzepatide cannot be compounded from bulk substances by US regulated outsourcing facilities. Pepti positions tirzepatide for Research use only. Read the GLP-1 2026 update →
Lot TIR-10HPLC ≥ 99%MS confirmed5 / 10 / 15 / 30 mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Tirzepatide |
|---|---|
| CAS number | 2023788-19-2 |
| Class | Dual GIP / GLP-1 receptor agonist (research) |
| Molecular weight | ≈ 4813.5 g/mol |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5 mg, 10 mg, 15 mg, 30 mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | 2–8 °C protected from light; long-term −20 °C |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
All tirzepatide quotes require a destination country and buyer track. Inquiries from US regulated facilities are answered with the regulatory bulk-substance framework proposal and routed to non-GLP-1 alternatives.
Documentation
Batch documentation support for tirzepatide lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope is confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the tirzepatide reference profile.
Destination check
Buyer track and destination country reviewed against the FDA 2026 regulated bulk-substance bulks proposal before quoting.
FAQ
Tirzepatide — frequently asked by B2B buyers.
Why is tirzepatide marked research-use on this site?
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework. If finalized, US regulated outsourcing facilities cannot compound tirzepatide from bulk substances. Pepti positions tirzepatide for research and private-label brand evaluation worldwide rather than US regulated.
Which markets do you serve for tirzepatide?
Latin America, Southeast Asia, parts of the Middle East, and select EMEA distributors with appropriate local registration. Buyer track and destination are confirmed before quoting.
Can research labs source tirzepatide?
Yes — lyophilized tirzepatide is supplied for laboratory research with COA, HPLC, and MS. Research inquiries are reviewed before quoting.
What is the MOQ for OEM tirzepatide brand evaluation?
Sample lots from 100 vials; production lots from 500 vials. OEM-branded packaging (vial label, carton, document pack) is scheduled in 2,000-vial batches.
What does your COA report?
HPLC purity (target ≥99%), MS identity, water content, related-substance profile on request, and lot traceability tied to the document pack.
Related compounds